- Home
- DSS vs MYNZ Comparison
DSS vs MYNZ Comparison
Compare DSS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSS | MYNZ |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DSS | MYNZ |
|---|---|---|
| Price | $0.92 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 254.6K | ★ 429.8K |
| Earning Date | 11-14-2025 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,046,000.00 | $659,935.00 |
| Revenue This Year | $14.93 | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $0.72 | $0.92 |
| 52 Week High | $1.90 | $8.16 |
Technical Indicators
Market Signals| Indicator | DSS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.